Oncternal Therapeutics to Report Very first Quarter 2021 Fiscal Success and Give Enterprise Update
SAN DIEGO, April 29, 2021 (World NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a medical-phase
Oncternal
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December